Rodriguez-Otero, PaulaVictoria Mateos, MariaMartinez-Lopez, JoaquinHernandez, Miguel TOcio, Enrique MRosinol, LauraMartinez, RafaelTeruel, Ana IsabelGutierrez, Norma CBargay Lleonart, JoanBengoechea, EnriqueGonzalez, YolandaPerez de Oteyza, JaimeGironella, MercedesNunez-Cordoba, Jorge MEncinas, CristinaMartin, JesusCabrera, CarmenPalomera, Luisde Arriba, FelipeCedena, Maria TeresaPuig, NoemiOriol, AlbertPaiva, BrunoBlade, JoanLahuerta, Juan JoseSan Miguel, Jesus F2024-09-102024-09-102019-03-18Rodriguez-Otero P, Mateos MV, Martinez-Lopez J, Hernandez MT, Ocio EM, Rosinol L, et al. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer J. 2019 Mar 18;9:36.2044-5385http://hdl.handle.net/20.500.13003/17583https://hdl.handle.net/20.500.12105/22778Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.enghttp://creativecommons.org/licenses/by/4.0/AgedMaleMultiple MyelomaFemaleHumansMonoclonal Gammopathy of Undetermined Significanceresearch articleAttribution 4.0 International3088613993610.1038/s41408-019-0176-xBlood Cancer Journalopen accessHumanosGammopatía Monoclonal de Relevancia IndeterminadaAncianoMieloma MúltipleFemeninoMasculino2-s2.0-85063024454462349100002L626798367